News

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...
Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) agonists, this class of medications mimics a natural hormone the small ...
Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...
AURORA, CO / ACCESS Newswire / March 29, 2025 / A novel study of a semaglutide, a glucagon-like peptide-1 (GLP-1) agonist used to treat type 2 diabetes, obesity and cardiovascular disease, semaglutide ...
stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound clinical impact for our patients who now have an oral option to improve ...